Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.

Shi Y, Li J, Kennedy LJ, Tao S, Hernández AS, Lai Z, Chen S, Wong H, Zhu J, Trehan A, Lim NK, Zhang H, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Muckelbauer J, Chang C, Krystek SR, Li YX, Hosagrahara V, Zhang L, Kadiyala P, Xu C, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA.

ACS Med Chem Lett. 2016 Apr 4;7(6):590-4. doi: 10.1021/acsmedchemlett.6b00033. eCollection 2016 Jun 9.


Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.

Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, Meyers D, Low S, Russo K, DiBella R, Denhez F, Gao M, Myers J, Duke G, Witmer M, Miao B, Ho SP, Khan J, Parker RA.

J Pharmacol Exp Ther. 2014 Aug;350(2):412-24. doi: 10.1124/jpet.114.214221. Epub 2014 Jun 10.


Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation.

Ye XY, Chen S, Zhang H, Locke KT, O'Malley K, Zhang L, Srivastava R, Miao B, Meyers D, Monshizadegan H, Search D, Grimm D, Zhang R, Lippy J, Twamley C, Muckelbauer JK, Chang C, An Y, Hosagrahara V, Zhang L, Yang TJ, Mukherjee R, Cheng PT, Tino JA.

Bioorg Med Chem Lett. 2010 May 1;20(9):2933-7. doi: 10.1016/j.bmcl.2010.03.019. Epub 2010 Mar 7.


Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).

Li J, Kennedy LJ, Shi Y, Tao S, Ye XY, Chen SY, Wang Y, Hernández AS, Wang W, Devasthale PV, Chen S, Lai Z, Zhang H, Wu S, Smirk RA, Bolton SA, Ryono DE, Zhang H, Lim NK, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Kadiyala P, Hosagrahara V, Zhang L, Xu C, Li YX, Muckelbauer JK, Chang C, An Y, Krystek SR, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA.

J Med Chem. 2010 Apr 8;53(7):2854-64. doi: 10.1021/jm9016812.


Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.

Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O'Malley KM, Zhang L, Li J, Shi Y, Kennedy LJ, Blanar M, Cheng PT, Tino J, Srivastava RA.

J Pharmacol Exp Ther. 2008 Dec;327(3):716-26. doi: 10.1124/jpet.108.143271. Epub 2008 Sep 17.


(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.

Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R, Sitkoff D, Monshizadegan H, Yin X, Ryan CS, Zhang R, Giancarli M, Bird E, Chang M, Chen X, Setters R, Search D, Zhuang S, Nguyen-Tran V, Cuff CA, Harrity T, Darienzo CJ, Li T, Reeves RA, Blanar MA, Barrish JC, Zahler R, Robl JA.

J Med Chem. 2008 May 8;51(9):2722-33. doi: 10.1021/jm800001n. Epub 2008 Apr 15.


The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins.

Madsen CS, Janovitz E, Zhang R, Nguyen-Tran V, Ryan CS, Yin X, Monshizadegan H, Chang M, D'Arienzo C, Scheer S, Setters R, Search D, Chen X, Zhuang S, Kunselman L, Peters A, Harrity T, Apedo A, Huang C, Cuff CA, Kowala MC, Blanar MA, Sun CQ, Robl JA, Stein PD.

J Pharmacol Exp Ther. 2008 Feb;324(2):576-86. Epub 2007 Nov 6.


A switch in enantiomer preference between mitochondrial F1F0-ATPase chemotypes.

Bisaha SN, Malley MF, Pudzianowski A, Monshizadegan H, Wang P, Madsen CS, Gougoutas JZ, Stein PD.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2749-51.


Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.

Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, Humphreys WG, Lan SJ, Ewing WR, Carlson KE, Kowala MC, Zahler R, Macor JE.

J Med Chem. 2005 Jan 13;48(1):171-9.


Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.

Grover GJ, Atwal KS, Sleph PG, Wang FL, Monshizadegan H, Monticello T, Green DW.

Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1747-55. Erratum in: Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H484.


Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.

Hamann LG, Ding CZ, Miller AV, Madsen CS, Wang P, Stein PD, Pudzianowski AT, Green DW, Monshizadegan H, Atwal KS.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1031-4.


Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.

Atwal KS, Wang P, Rogers WL, Sleph P, Monshizadegan H, Ferrara FN, Traeger S, Green DW, Grover GJ.

J Med Chem. 2004 Feb 26;47(5):1081-4.


Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.

Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, Gu Z, Kane B, Fadnis L, Baska RA, Beyer S, Arthur S, Dickinson K, Zhang D, Perrone M, Ferrer P, Giancarli M, Baumann J, Bird E, Panchal B, Yang Y, Trippodo N, Barrish J, Macor JE.

J Pharmacol Exp Ther. 2004 Apr;309(1):275-84. Epub 2004 Jan 12.


Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists.

Tellew JE, Baska RA, Beyer SM, Carlson KE, Cornelius LA, Fadnis L, Gu Z, Kunst BL, Kowala MC, Monshizadegan H, Murugesan N, Ryan CS, Valentine MT, Yang Y, Macor JE.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1093-6.


Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.

Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Panchal B, Valentine MT, Chong S, Morrison RA, Carlson KE, Powell JR, Moreland S, Barrish JC, Kowala MC, Macor JE.

J Med Chem. 2002 Aug 29;45(18):3829-35.


Role of endothelin receptor subtype B (ET-B) in myocardial ischemia.

Sargent CA, Liu EC, Chao CC, Monshizadegan H, Webb ML, Grover GJ.

Life Sci. 1994;55(23):1833-44. Erratum in: Life Sci 1994 Dec 23;56(5):361.


Expression of endothelin receptor subtypes in rabbit saphenous vein.

Webb ML, Liu EC, Monshizadegan H, Chao CC, Lynch J, Fisher SM, Rose PM.

Mol Pharmacol. 1993 Nov;44(5):959-65.


Binding and signal transduction of the cloned vascular angiotensin II (AT1a) receptor cDNA stably expressed in Chinese hamster ovary cells.

Webb ML, Monshizadegan H, Dickinson KE, Serafino R, Moreland S, Michel I, Seiler SM, Murphy TJ.

Regul Pept. 1993 Mar 19;44(2):131-9.


Binding and function of a potent new thromboxane receptor antagonist, BMS 180,291, in human platelets.

Webb ML, Liu EC, Monshizadegan H, Hedberg A, Misra RN, Goldenberg H, Harris DN.

J Pharmacol Exp Ther. 1993 Mar;264(3):1387-94.


Binding of 125I-endothelin-1 and 125I-endothelin-3 in rabbit saphenous vein: evidence for an atypical ET binding component.

Liu EC, Monshizadegan H, Chao CC, Lynch J, Fisher SM, Rose PM, Webb ML.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S132-5.


The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta.

Webb ML, Dickinson KE, Delaney CL, Liu EC, Serafino R, Cohen RB, Monshizadegan H, Moreland S.

Biochem Biophys Res Commun. 1992 Jun 30;185(3):887-92.


Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells.

Webb ML, Liu EC, Cohen RB, Hedberg A, Bogosian EA, Monshizadegan H, Molloy C, Serafino R, Moreland S, Murphy TJ, et al.

Peptides. 1992 May-Jun;13(3):499-508.


Supplemental Content

Loading ...
Support Center